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Abstract Mutations in the GJB2 gene are the most frequently found mutations in patients with nonsyndromic
hearing impairment. However, the mutation spectrum and prevalence of mutations vary among different ethnic
groups. Every year, 30, 000 babies are born with congenital hearing impairment in China. In order to provide
appropriate genetic testing and counseling to the family, we investigated the molecular etiology of nonsyndromic
deafness in 135 unrelated school children attending Chifeng Municipal Special Education School in Inner
Mongolia, China. The coding exon of the GJB2 gene was PCR amplified and sequenced. In addition, the 12S
rRNA gene and tRNAser(UCN) of mitochondrial genome were screened for mutations responsible for hearing
impairment. Sixty four GJB2 mutant alleles, including 60 confirmed pathogenic alleles and 4 unclassified variants,
were identified in 31.1% (42/135) of the subjects. Twenty two subjects carried two pathogenic mutations and 20
subjects carried one mutant allele, including one subject with one autosomal dominant mutation. The 235delC was
the most common mutation accounting for 65.6% (42/64) GJB2 mutant alleles. When compared to other Asian
populations, our subject cohort had higher frequency of 235delC mutation than the Japanese population. The GJB2
mutant alleles account for 23.7% (64/270) of all chromosomes responsible for nonsyndromic hearing impairment.
Testing of the 4 most prevalent deleterious frame shift mutations(235delC, 299_300delAT, 176_191del16, and 560_
605ins46) in this cohort detected 90% of all GJB2 mutant alleles. These results demonstrate that effective genetic
testing of the GJB2 gene for patients and families with nonsyndromic hearing impairment is possible in the
Chinese population. Since the most common 309kb GJB6 deletion is not detected and only one 1555 A>G
mutation in mitochondrial DNA is detected in our patients, investigation of mutations in other nuclear genes and/or
environmental factors responsible for nonsyndromic hearing impairment in the Chinese population is necessary.
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Introduction
Hearing impairment is the most common
neurosensory disorder in humans that has an incidence
of approximately 1 in 1000 children. About two thirds
of cases have a genetic etiology［1］. Hereditary deafness
is genetically heterogeneous. Nonsyndromic deafness
accounts for 60-70% of inherited hearing impairment
and involves more than 100 different genes with
autosomal dominant(DFNA), autosomal recessive
(DNFB), X-linked(DFN), and maternal inheritance［２］.
The most common cause for nonsyndromic autosomal
recessive hearing loss is mutations in Connexin 26, a
gap junction protein encoded by the GJB2 gene［3－ 10］.
However, about 30% to 40% of hereditary deafness is
syndromic, presenting with other clinical features in
addition to hearing impairment.
Connexins are transmembrane proteins. Six
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monomers of connexin proteins associate to form a
transmembrane hexameric gap junction hemi-channel
called a connexon. Connexons embedded in the
surfaces of adjacent cells associate to form an
intercellular channel ［11］. In the inner ear, connexin 26
can be in association with other connexins to form
heteromeric connexons, and gap junction channels can
be homotypic or heterotypic. The hair cells use
connexin 26 gap junction channels to recycle the
potassium ion as part of the mechanism of auditory
signal transduction［12］.
In deed, mutations in three connexin(Cx) genes,
GJB2 for Cx26, GJB6 for Cx30, and GJB3 for Cx31,
have been identified and known to cause hearing im-
pairment ［13 － 15］. However, sequence analysis of the
GJB2 gene in subjects with autosomal recessive hear-
ing impairment has revealed a puzzling problem: a
high number of patients carry only one mutant allele.
Some of these families show clear evidence of linkage
to the DFNB1 locus, which contains two genes, GJB2
and GJB6［3, 16］. Further analysis demonstrates that a de-
letion truncating the GJB6 gene, encoding connexin
30, near GJB2 accompanies in trans in heterozygous af-
fected subjects［17,18］.
To date, more than 100 mutations,
polymorphisms, and unclassified variants have been
described in the GJB2 to account for 10%-50% of
molecular etiology in patients with nonsyndromic
hearing impairment (http://davinci.crg.es/deafness).
The mutation spectrum and prevalence of mutations
vary significantly among different ethnic groups. Three
mutations, 35delG, 167delT, and 235delC, are found to
be the most frequent mutations in Caucasian,
Ashkenazi Jewish, and Asian populations, respectively
［3, 5-10, 13, 16, 19, 20］. A recent multicenter study reported that
the 35delG mutation accounted for 72.44% of GJB2
mutant alleles in 1,718 patients with biallelic DFNB1
mutations, including delGJB6-D13S1830 ［21］. This
group of patients consisted of 90% white. In Ashkenazi
Jews, 35delG and 167delT account for 96% of the
GJB2 mutant alleles［22］. However, the 35delG mutation
is rarely found in Asian patients. Instead, the 235delC
mutation is the most prevalent in the Japanese,
Korean, and Taiwanese［6, 10, 19, 23, 24］. Due to the
broad mutation spectrum and prevalence of mutations
in various ethnic groups, identification of mutations
and their frequencies in a specific ethnic group is
important in providing accurate genetic counseling and
risk assessment for patients and families.
Although the majority of cases with hereditary
hearing loss are caused by nuclear gene defects, in
recent years, it has become clear that mitochondrial
genes that are essential for energy metabolism can also
cause hearing impairment. In fact, sensorineural
hearing loss is one of the most prevalent and
recognized clinical features of mitochondrial
cytopathies ［2, 25］. Mutations in mitochondrial
DNA(mtDNA) can also cause non-syndromic hearing
loss［25－ 27］. The most well studied mutation is the(1555
A>G) mutation in the mitochondrial 12S rRNA gene
causing the nonsydromic hypersensitivity to ototoxic
effects of aminoglycosides by increased binding of
aminoglycosides to mitochondrial ribosomes, leading
to the disruption of mitochondrial protein synthesis［28,
29］. Another recently identified mutation in the
mitochondrial 12S rRNA gene is the 1494 T>C in the
conserved stem structure of 12S rRNA ［30］. Other
nucleotide changes at position 961 in the 12S rRNA
gene have been found to be associated with hearing
loss, but their pathogenic mechanism in the
predisposition of carriers to aminoglycoside toxicity is
much less clear［31, 32］. Several mutations(7445 A>G,
7472insC, 7510 T>C, 7511 T>C, and 7512 T>C) in the
mitochondrial tRNAser(UCN) gene are also known to cause
maternally inherited non-syndromic hearing loss
(MIHL) by disturbing the tRNA structure and
function［2, 25, 33］.
The mtDNA 1555 A>G mutation accounts for a
small fraction of patients with nonsyndromic hearing
loss, that is usually post-lingual. The frequency has
been reported to be between 0.6% to 2.5% among
different Caucasian groups［34 － 38］, and higher in Asian
countries: 2.9% , 3% , and 5.3% in Chinese, Japanese,
and Indonesian cohorts, respectively［39 －41］. However,
the incidence of 1555 A>G mutation in
aminoglycoside induced ototoxicity is much higher. In
a Japanese study, the 1555 A>G mutation was found in
as high as 33% of patients with a history of
aminoglycoside exposure ［39］. In contrast, 13% of
Chinese pediatric patients with aminoglycoside
ototoxicity carry the 1555 A>G mutation［41］.
In China, it is estimated that 30,000 babies are
born with congenital hearing impairment in 20,000,000
live births every year ［42］. However, the molecular
etiology of Chinese deaf children has not been
thoroughly investigated and effective genetic testing is
yet to be offered. Since China is a big country with
more than 56 different ethnic groups(including Han,
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Zhuang, Man, Mongolian, Hui, Miao,Yi, Wa, Bai,
Zang, Wei, Qiang, NaXi, etc) clustered in different
parts of China, comprehensive genetic analysis of deaf
children in different regions of China needs to be
performed to obtain valid epidemiological information
in order to provide effective genetic testing and
accurate counseling. Recently, we screened for the
mtDNA 1555 A>G mutation in Chinese deaf children
in various regions of China and found that this
mutation accounted for about 2.83% of nonsyndromic
hearing impaired children ［42］. Surprisingly, this
mutation occurred at a much lower frequency in
patients from Inner Mongolia when compared to other
parts of China. To understand more about the genetic
etiology of deafness among the Inner Mongolian
population, we performed a comprehensive genetic
analysis of the GJB2 in a cohort of subjects attending
the Chifeng Municipal Special Education School. We
found that 38 of the 135(28.1% ) patients with
nonsyndromic hearing impairment carried confirmed
pathogenic mutations and 4 harbored unclassified
variants in the GJB2. Deletion of the GJB6 gene was
not detected in the heterozygous GJB2 mutation
carriers.
Material and Methods
Patients and DNA samples
A total of 141 deaf students from 135 unrelated
families attended the Chifeng Municipal Special Educa-
tion School in Inner Mongolia, China, of which 135
probands from different families were included in this
study. The Chifeng Municipal Special Education
School is the only school for the deaf in the area. All
children with moderate to profound bilateral hearing
loss from the city of Chifeng and from the area within
500 km radius come to this school. More than 95% of
the students participated in the study. The subject co-
hort consisted of 85 males and 50 females aging from
3 to 20 years (average 13.2±3.6 years). There were 94
Han, 31 Mongolian, 7 Man, and 3 Hui Chinese chil-
dren in this group. The study was conducted according
to a protocol approved by the Ethics Committee of the
Chinese PLA General Hospital. Informed consents
were obtained from legal guardians prior to collecting
blood samples. Parents were interviewed for the age of
hearing loss diagnosis, family history, maternal health
during pregnancy, and the child's medical history in-
cluding infection, head or brain injury, and use of ami-
noglycoside antibiotics. All subjects showed moderate
to profound bilateral sensorineural hearing loss on au-
diograms. DNA specimens from all subjects and 100
race-matched students with normal hearing (deter-
mined by teachers and otolaryngologists) were se-
quenced for the presence of mutations and polymor-
phisms in the GJB2 gene and in 12S rRNA and tRNAs-
er(UCN) mtDNA genes. DNA was extracted from peripher-
al blood leukocytes using a commercially available
DNA extraction kit(Watson Biotechnologies Inc,
Shanghai, China).
Mutational analysis
DNA sequence analysis of the GJB2 gene was
performed via PCR amplification of the coding exon
plus approximately 50 bp of the flanking intron regions
followed by Big Dye sequencing. The sequence results
were analyzed using an ABI 3100 DNA sequencing
machine (ABI, Foster City, USA.) running on ABI
3100 Analysis Software v.3.7 NT according to
manufacturer's manual. Patients with one GJB2 mutant
allele were analyzed for the presence of GJB6 gene
deletion using the PCR method［17, 18］. A positive control
provided by Balin Wu(Department of Laboratory
Medicine, Children's Hospital and Harvard Medical
School, USA.) was used for detection of GJB6 gene
deletion. Finally, part of the mitochondrial 12S rRNA
gene containing the 1555 A>G mutation (nt611 to
nt2007) and the tRNAser region(nt7148 to nt8095)
were sequenced in all subjects.
Results
Among the 135 cases studied, 73 were pre-lingual
hearing loss including 56 cases of congenital deafness.
Twenty-eight cases were post-lingual hearing loss with
an average age of onset at 2.93 ± 1.48 years. The onset
age of the remaining 34 cases were unclear. In
addition, 38 cases (18 pre-lingual and 20 post-lingual)
had clear history of aminoglycoside usage with an
average age of hearing loss onset at 1.67 ± 1.6 years.
The average age of hearing loss onset in subjects
without history of aminoglycoside usage was 0.681 ±
1.078 years, significantly lower than that in those with
aminoglycoside usage（P< 0.001）.
GJB2 mutations
Sequence analysis of the GJB2 revealed that 22
subjects carried 2 confirmed pathogenic mutations and
one had a R75W mutation, which has been reported to
cause autosomal dominant syndromic deafness with
palmoplanter keratoderma ［43］ (Table 1). Sixteen
subjects, including the one with autosomal dominant
·· 83
Journal of Otology 2007 Vol. 2 No. 2
Novel alterations are in bold and italic. Mutations or polymorphisms with unknown phase are in parenthesis.
aR75W has been reported in autosomal dominant syndromic deafness with palmoplantar keratoderma (PPK) (Richard et al 1998b).
bV198M, V63L, and V153A are unclassified variantsl with unknown pathogenicity. V63L has been reported by (Hwa et al. 2003). V63A have been re-
ported by Tang et al (2006 in press) as a novel alteration and V153I (not V153A) can be found in http://davinci.crg.es/deafness as a.polymorphism.
cV37I has been reported as a pathogenic mutation and as a polymorphism. In this report, we count it as a polymorphism (Table 3).
dAll patients listed here are from unrelated families.
eTM=transmembrane domain, EC=extracellular domain, IC=intracellular domain
Allele 1
Nucleotide
Change
c.235delC
c.235delC
c.235delC
c.235delC
c.560_605ins46
c.299_300delAT
(c.223C>T)
c.235delC
c.299_300delAT
c.155_158delTCTG
(c.592G>A)
c.187G>T
(c.458T>C)
c.109G>A
(c.109G>A)
c.79G>A, c.341A>G
c.79G>A, c.341A>G
c.341A>G
c.79G>A
consequence or
amino acid
change
frame shift
frame shift
frame shift
frame shift
frame shift
frame shift
(aR75W) eEC1
Autosomal dominant
frame shift
frame shift
frame shift
(bV198M) eTM4
bV63L e(EC1)
(bV153A) eEC2
cV37I , e TM1
(cV37I)
V27I, E114G e (IC2)
V27I, E114G
E114G
V27I TM1
category
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
aPathogenicPPK
pathogenic
pathogenic
pathogenic
novel
reported
novel
csee note
csee note
polymorphism
polymorphism
polymorphism
polymorphism
Allele 2
nucleotide change
c.235delC
c.299_300delAT
c.176_191del16
c.257C>G
c.560_.605ins46
c.176_191del16
(c.79G>A, c.341A>G)
-
-
-
(c.79G>A, c.341A>G)
-
(c.608T>C)
-
(c.79G>A, c.341A>G)
-
c.79G>A, c.341A>G
-
-
consequence or
amino acid change
frame shift
frame shift
frame shift
p.T86R e(TM2)
frame shift
frame shift
(V27I,E114G)
(V27I, E114G)
(I203T)
(V27I,E114G)
V27I, E114G
category
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
pathogenic
polymorphism
polymorphism
polymorphism
polymorphism
polymorphism
Number of
patientsd
14
3
1
1
1
2
1
9
5
1
2
1
1
2
1
44
2
1
9
Table 1. Genotype of patients with mutations in GJB2 gene.
R75W mutation, were heterozygous for one pathogenic
mutant allele and 4 were heterozygous for one
unclassified novel variant whose pathogenicity has not
been determined(Table 1). In addition, 3 subjects
carried the heterozygous allele of V37I, whose role as
either a pathogenic mutation or a polymorphism has
been in great debate［8, 19, 20, 24, 44-46］. Thus, 23 of the 135
unrelated deaf families (17.04%) in Chifeng City, Inner
Mongolia, had confirmed molecular etiology of
nonsyndromic hearing impairment(22 autosomal
recessive and 1 autosomal dominant) in the GJB2.
Seven types of pathogenic mutations were
identified, including 5 frameshift mutations (235delC,
299_300delAT, 176_191del16, 560_605ins46, and 155_
158delTCTG) and 2 missense mutations (T86R and
R75W) (Table 1). The most prevalent mutation in this
subject cohort was 235delC, which has also been
reported to be the most prevalent in other Asian
populations［6, 19］. Fourteen subjects were homozygous
for 235delC mutation: 5 compound heterozygous with
another pathogenic mutation and 9 heterozygous
carriers of 235delC mutation only(Tables 1). Four
novel alterations were identified, including a frame
shift pathogenic 155_158delTCTG mutation and three
unclassified missense variants(V198M, V63L and
V153A, see Tables 1 and 2). Overall, 64 mutant alleles
(including the unclassified missense variants and one
autosomal dominant, R75W, but excluding the V37I
variant) were identified in 42 unrelated subjects. The
235delC alone accounted for 65.6% (42/64) of the total
mutant alleles. Two mutations, 235delC and 299delAT
accounted for 81.3% (52/64) of the GJB2 mutations in
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our patients, in comparison to 91% in a different
Chinese population ［46］ and 97% in the Taiwanese
population［23］. G45E and G4D were not detected in this
group of subjects. Three T123N alleles were detected
in our control but not in the test group.
The mutation spectra of the GJB2 did not seem to
vary among different ethnic groups in Chifeng area,
with 235delC being the most common mutation in all
groups. The 299_300delAT mutation was found in 7
Han, 2 Mongolian and 1 Hui subjects. The 560_
605ins46 deleterious mutation was found in 1 Man
subject. The 176_191del16 was detected in 2 Han and
1 Mongolian subjects, and the 155_158delTCTG in 1
Man subject. Four out of the 7(57%) Man subjects, and
about 30% of subjects from other ethnic backgrounds
carried the GJB2 mutations. The difference of GJB2
detection rate among these 4 ethnic groups was not
significant (χ=2.4893, P value 0.4772).
GJB2 polymorphisms
GJB2 gene analysis in the control subjects showed
4 deleterious mutations(Table 5), giving a carrier rate
of 4%(4/100). Three T123N alleles and 8 V37I alleles
were also detected.
Correlation of genotype with onset age of hearing loss
and clinical phenotype
Excluding heterozygous patients with 1 mutant
allele but including those with R75W, the average
onset age of hearing loss in subjects with GJB2
mutations was 0.97 ± 0.22 years, while that in those
without GJB2 mutations was 1.01 ± 1.37 years (P =
0.9689 and t= 0.039).
Deletion in GJB6 and 1555 A>G mutation
According to Del Castillo et al., a good proportion
of patients heterozygous for one mutant allele in the
GJB2 has a 342 kb(now considered as 309 kb) deletion
in the GJB6［17, 18, 47］. None of our heterozygous subjects
with one GJB2 mutant allele showed this deletion in
the GJB6 gene. The 1555 A>G mutation in the mtDNA
12S rRNA gene was detected in one subject who had a
clear history of aminoglycoside usage. None of the
remaining 37 subjects with history of aminoglycoside
usage had mutations in the 12S rRNA gene. Mutations
in tRNAser(UCN) were not detected in any of our subjects.
Discussion
Previous reports have suggested that the
prevalence of GJB2 mutations among different ethnic
groups varies. The carrier rate of deleterious GJB2
mutation among the normal subjects in this study was
4% . The same carrier rate is 2% in Korea, 2.08% in
Japan, 2.55% in Taiwan, 4.76% among Ashkenazi
Jews, and 3.01%, in Midwestern United States. In our
subjects, the most common mutation in Caucasians , i.
e., 35delG, was not found. Instead, the 235delC
mutation accounted for 65.6% of GJB2 mutant alleles,
supporting the notion that the 235delC mutation in the
connexin 26 gene is the most prevalent mutation in
Asian populations, including the Han Chinese. Four
additional frameshift, pathogenic mutations were
found, including one novel mutation c.155_
158delTCTG. The 299delAT, 176_191del16, and 560_
605ins46 mutations have all been reported in
Taiwanese, Japanese and Korean patients［6, 10, 19, 23, 24］.
These five frame shift mutations accounted for 90.6%
(58/64) of all GJB2 mutations found in this subject
group. This is the highest level of mutation detection
rate among Asian populations. Detection rates at
approximately 41% and 57% have been documented in
two Japanese reports, 67% in one Taiwanese paper and
73% in one Korean study(Table 2)［6, 10, 19, 23, 24］. In
addition to the most common 235delC mutation, G45E
accounts for 16% of the Japanese GJB2 mutations,
while G4D accounts for 10.6% of Taiwanese GJB2
mutant alleles(Hwa et al. 2003; Ohtsuka et al. 2003).
Neither of these mutations was detected in our subjects.
The differences in GJB2 mutation spectrum and
prevalence among different Asian populations suggest
that GJB2 mutations may also be different among
different ethnic groups in China. The top 6 largest
ethnic groups of the Chinese nation are: Han, Man,
Mongolian, Hui, Zhuang and Miao. The Han comprises
the majority of the Chinese population(91.6% ) and
70% of our study subjects. Rare deleterious mutations
were detected in 4 ethnic groups in this study. There
are no significant differences in GJB2 mutation spectra
among the different ethnic groups in this Chinese
cohort, although the relative sample sizes of the
non-Han subjects are small.
The missense mutation, T86R, was found in
compound heterozygous with 235delC mutation in 1
subject. Although not listed in the GJB2 mutation
database(http://davinci.crg.es/deafness), this mutation
has been reported in 3 Japanese patients［10］. The 15 year
old Chinese female with R75W mutation in the current
study reported no history of ototoxic medication
exposure. She developed thickening and peeling of the
skin at medial and lateral sides of both hands and feet
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when she was 1 year of age. She was treated with
traditional Chinese herbal medicines with no
significant improvement. Audiometric testing showed
moderate high frequency hearing loss in her father and
normal hearing in her mother. Both parents had no skin
lesions. GJB2 sequencing of the parents showed they
were not R75W mutation carriers, suggesting that the
R75W in the subject was a de novel mutation. This
mutation has been previously reported in association
with autosomal dominant deafness and palmoplantar
keratoderma［43］. The R75 is located at an evolutionarily
conserved region of extracellular domain 1, where
change of the highly positively charged arginine
residue to highly hydrophobic aromatic amino acid
tryptophan apparently distorts the structure and
function of the connexin 26 protein molecule. Three
missense variants; V63L, V153A, and V198M, are
located in extracelluar domain 1, 2, and
transmembrane span 4, respectively, of the connexin
26 protein. Although GJB2 mutation spectra from
different Asian populations share the same most
common 235delC mutation, few of the rare variants
overlap(Table 2), suggesting that the rare variants have
evolved recently in different geographic populations.
The V153A and V198M are novel variants and not
reported in the database (http://davinci.crg.es/
deafness). However, V63L has been found in 1
Taiwanese patient ［24］. These three variants likely
contribute to the pathogenesis of deafness, because (a)
they have been detected only in the patient group and
not in 394 Japanese, 864 Taiwanese, and 494 Korean
subjects, and(b) they are evolutionarily conserved from
xenopus, mouse, rat, sheep, Orangutan and human. In
fact, they are invariably valine at all three amino acid
positions throughout evolution, except that V153 is a
leucine in Xenopus (data not shown). These mutations
were found heterozygous in 4 unrelated subjects who
carried only one mutant allele. It is not clear if they
represent autosomal dominant mutations, or they are
autosomal recessive with the second mutant allele not
yet identified. The second mutant allele may be either
in the same gene (deep in introns, at the promoter site,
or untranslated regions) or different genes(bigenic
synergistic heterozygous mutations) ［17, 48］.
Heterozygous mutation carriers may be more
susceptible to environmental factors that cause deafness
［49］. Alternatively, these patients may be simply
coincidental carriers whose deafness is caused by
non-genetic environmental factors.
The pathogenicity of V37I is controversial. The
V37I variant has been considered as a pathogenic
mutation in the Japanese studies, but not found in any
of the Korean control or patient populations［6, 10, 19］. In a
recent multicenter study, the V37I mutation was found
to be associated with mild to moderate hearing
impairment (median 25-40 dB HL) ［21］. This mutation
was the second most common mutation in the
Japanese, accounting for 21% of all GJB2 mutant
alleles. It is found at lower frequencies in patients than
in controls in Chinese and Taiwanese studies［23, 24, 46］
(Table 3). In our study, V37I allele is present at 4% (8/
200) in the control population, but only 1.1% (3/270)
in the test group. The V37I variant does not appear to
be a disease causing mutation among the Chinese. The
discrepancies may be due to patients' genetic and
environmental backgrounds. All our subjects with
V37I are heterozygous without a second mutant allele.
Our data do not support the pathogenicity of V37I
variant, although the possible predisposition effect by
V37I on patients who have been exposed to
detrimental environmental factors cannot be ruled out.
Table 3 also lists the frequencies of four common
GJB2 polymorphisms, V27I, E114G, I203T, and
T123N in Asian populations. Although allele
frequencies among different studies are different, the
difference between test and control groups is
statistically significant for V27I, E114G, but not for
I203T in this study (P<0.001 for V27I and E114G, and
P = 0.436 for I203T). The T123N is an unclassified
variant. It is counted as polymorphism in Taiwanese
studies, but as a pathogenic mutation in Japanese and
Korean studies. In one Taiwanese study, 1 T123N
allele was found in 648 patient chromosomes and 15
T123N alleles in 864 control chromosomes. We found
3 T123N alleles in the control subjects but none in the
test subjects. Like the Taiwanese study, these data do
not support the pathogenicity of T123N. V27I, E114G,
and I203T are considered as polymorphisms in all
reported studies. The nonsense mutation Y136X has
been detected at 10% and 14.3% among patients in two
Japanese studies but not in other Asian populations.
Mutations in the GJB2 gene account for
10%-50% of autosomal recessive nonsyndromic
hearing impairment world wide ［50, 51］. Table 4 lists
frequencies of GJB2 mutations reported in some
patient populations. The ethnic background and patient
ascertainment(multiple or single affected family
members) account for the heterogeneity of mutations
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Numbers in the parentheses are the percentages of mutant alleles in total GJB2 mutant alleles identified.
a total number of chromosome studied=number of patients x 2
b AD: Autosomal dominant mutations
c V37I was only considered pathogenic mutation in Japanese studies. It is not included in the calculation in other studies.
d T123N is an unclassified variant. It was counted as a polymorphism in Taiwanese1 study, but counted as a pathogenic mutation in Japanese and
Korean studies. In Taiwanese study, 1 T123N allele was found in 648 patient chromosomes and 15 T123N alleles were found in 864 control chro-
mosomes.
e Shi's study included 20 new born patients with severe nonsyndromic hearing impairment.
f Abe's study included families containing one or two affected siblings.
g E114G was considered as a pathogenic mutation in Park's study. It is not included in this Table.
aTotal number of chromosomes
Total mutant alleles identified
% of GJB2 mutation in total
235delC
299_300delAT
176_191del16
560_605ins46
155_158del4
T86R
R75W b(AD)
V198M
V153A
V63L
G4D
W77X
F191L
R184Q b (AD)
R75Q b (AD)
G130A
V43M
I30V
cV37I
G45E
Y136X
dT123N
R143W
I71T
A49V
S85P
35delG
E47*
unknown
references
Chinese 1
Our study
270
64 (100)
23.7
42 (65.6)
10 (15.6)
3 (4.7)
2 (3.1)
1 (1.6)
1 (1.6)
1 (1.6)
2 (3.1)
1 (1.6)
1 (1.6)
3 (1.1)
This study
Control
our study
200
1
2
8
3
1
This study
Chinese2
40
11 (100)
27.5
9 (82)
1 (9)
1 (9)
(Shi et
al. 2004)e
Taiwanese1
648
66 (100)
10.2
38(57.6)
5 (7.6)
1 (1.5)
1 (1.5)
7 (10.6)
4 (6)
3 (4.5)
2 (3)
2 (3)
1 (1.5)
1 (1.5)
1 (1.5)
58
1
(Hwa et al.
2003)
Taiwanese2
238
29 (100)
12.2
22 (76)
6 (21)
1 (3)
(Wang et
al. 2002)
Japanese1
2454
284 (100)
11.6
96(34)
8 (2.8)
12 (4.2)
1 (0.35)
3 (1.1)
4 (1.4)
61 (21)
45 (16)
30 (10)
11 (3.9)
8 (2.8)
4 (1.4)
1 (0.35)
(Ohtsuka
et al. 2003)
Japanese2
70
21 (100)
30
10 (47.6)
1 (4.8)
1 (4.8)
1 (4.8)
1 (4.8)
3 (14.3)
4 (19)
(Abe et
al. 2000)f
Korean
294
23 (100)
7.8
15 (65)
1 (4.3)
1 (4.3)
1 (4.3)
1 (4.3)
2 (8.7)
2 (8.7)
(Park et
al. 2000)
Table 2. GJB2 mutation spectrum among Asian populations.
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(Table 2) and the proportion of patients with two GJB2
mutant alleles. Patient populations containing more
unrelated subjects without family history have lower
chance of detection of two GJB2 mutant alleles and
higher percent one mutant allele detection than related
subjects. For example, double GJB2 mutant alleles are
found in approximately 5% in Korean, 10% in US
and 14% in German patient populations,
respectively［6, 9, 52］, whereas as high as 34% patients
carry double GJB2 mutant alleles in studies where
patients were ascertained through strong family
history ［25, 53］. In our study, 22 of 135 unrelated
patients(16.3% ) had two confirmed pathogenic
mutations, higher than reported by the two previous
Taiwanese studies(7% and 6% ), but lower than the
Japanese reports on families.
A significant portion of patients with GJB2
mutations have only one mutant allele. This also varies
among different populations and, in general, is in
reverse correlation with the proportion of patients
harboring two mutant alleles(Table 4). Excluding the
known autosomal dominant mutation R75W, but
Table 3. Comparison of allele frequencies of V37I, V27I, E114G, and I203T between patients and controls
variant
Total alleles
V37I
V27I
E114G
I203T
T123N
references
Our patients
270 (100)
3 (1.1)
62 (23)
51 (18.8)
2 (0.74)
0
This study
Our controls
200 (100)
8 (4)
79 (39.5)
57 (28.5)
6 (3)
3 (1.5)
This study
Chinese Patient/control
40(100)/100 (100)
0/3 (3)
6 (15)/39 (39)
3 (7.5)/31 (31)
0/0
0/1 (1)
(Shi et al. 2004)
Japanese Patient/
control
70 (100)/192 (100)
1 (1.5)/2 (0.7)
0/75 (25.5)
0/25 (8.5)
0/16 (5.4)
0/0
(Abe et al. 2000)
Taiwanese patient/control
648(100)/864 (100)
58 (9)/100 (11.6)
149 (23)/319 (37)
121 (19)/275 (32)
42 (6.5)/39 (4.5)
1(0.15)/14 (1.62)
(Hwa et al. 2003)
Korean/control
294(100)/200 (100)
0/0
97 (33)/80 (40)
90 (31)/40 (20)
0/3 (1.5)
1 (0.34)/0
(Park et al. 2000)
The numbers are number of alleles. The numbers in the parentheses are the percentage of the variant alleles in the total number of alleles.
Table 4. Comparison of frequencies of nonsyndromic deafness caused by mutations in GJB2 gene in different studies
Total
patients
Patients
with GJB2
mutation
2
mutations
1
mutationc
Total
mutant
alleles
references
Inner
Mongolia
a135
42
(b100, 31.1)
22(52.4,
16.3)
20
(46.6, 14.8)
64
(d23.7)
This study
Taiwanese
1
169
17
(100, 10)
12
(71, 7)
5
(29, 3)
29
(8.6)
(Wang
et al.
2002)
Taiwanese
2
324
48
(100, 15)
19
(40, 5.9)
29
(60, 9)
66
(10)
(Hwa et
al. 2003)
Chinese
20
6
(100, 30)
5
(83, 25)
1
(17, 5)
11
(27.5)
(Shi et
al. 2004)
Korean
147
16
(100, 11)
7
(44, 4.8 )
9
(56, 6.1 )
23
(7.8)
(Park et
al. 2000)
Japanese
35
11
(100, 31)
9
(82, 25.7)
2
(18, 5.7)
20
(29)
(Abe et
al. 2000)
US
(BCM)
610
113
(100, 18.5)
63
(56, 10.3)
50
(44, 8.2)
176
(14.4)
(Tang et
al. 2006)
Australia
n
74
18
(100, 24)
10
(56, 13.5)
8
(44, 10.8)
28
(18.9)
(Wilcox
et
al.2000)
UK
familial
142
61
(100, 43)
45
(74,32)
16
(26, 11)
106
(37)
(Hutchin
and
Cortopassi
2000)
French
104
43
(100, 41)
35
(81, 33.7)
8
(19, 7.7)
78
(37.5)
(Denoyel
le et al.
1999)
German
147
30
(100, 20)
21
(70, 14.3 )
9
(30, 6.1)
51
(17.1)
\(Gabriel
et al.
2001)
European
422
173
(100, 41)
129
(75, 30.6)
44
(25, 10.2)
302
(35.8)
(del
Castillo
et al.
a numbers are number of patients, including the allele of autosomal dominant mutations
b The numbers in the parenthesis stand for the percentage of patients in total number of deaf patients and patients carrying GJB2 mutations (with
two or 1 mutation), respectively, for the first and the second number.
cinclude the patients carrying autosomal dominant mutations and unclassified variants
dPercentage of mutant alleles identified in total number of chromosomes, for example, 64/274=23.7
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including the 4 subjects with unclassified variants, we
detected 19(14.07% ) cases with one GJB2 mutant
allele. Carriers of a single mutation in GJB2
demonstrate evidence of reduced hair-cell function［54］.
Thus, it is possible that these carriers are more likely
than non-carriers to develop hearing impairment in the
presence of other genetic defects or environmental
factors［49］. Indeed, a common 342 kb deletion (now
considered a 309 kb deletion) involving the coding
region of connexin 30(GJB6 gene) protein upstream of
the GJB2 gene has been identified and found to
account for up to 10% of DFNB1 alleles［18, 47］. In
addition, GJB2 mutations may act synergistically in the
presence of mtDNA 1555 A>G mutation with
aminoglycoside induced ototoxicity［55］. In this study,
deletion in the GJB6 was not detected in any of our
subjects. The 1555 A>G mutation was found in a
subject who had a history of aminoglycoside usage.
Hwa et al., in studying Taiwanese prelingual deaf
patients carrying one GJB2 mutant allele, did not find
any deletions or mutations in the GJB6, nor did they
find 1555 A>G mutation in mtDNA, consistent with
our results［24］.
In summary, this study revealed a unique GJB2
mutation spectrum in Chinese patients with
nonsyndromic hearing impairment. The 235delC
mutation is the most frequent mutations in deaf
patients in Inner Mongolia, China. Testing for 235delC
and 299_300delAT mutations detected 81.3% of GJB2
mutant alleles. Considering the small sample size, it is
possible that specific sub-ethnic group prevalent
mutations within the Chinese population exist but are
not demonstrated by this study. In order to provide
effective genetic testing and accurate counseling, it is
necessary to study the genetic etiology of hearing
impairment among sub-populations in China.
Furthermore, the molecular defects of more than 70%
of the patients with nonsyndromic hearing impairment
in China remain to be identified.
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